n°148

April 2014

Issue Contents
Editorial

Free  Pharma Corruption

p.88
"Regulatory capture" and other forms of institutionalised corruption harm patients' interest

Marketing Authorisations

Inhaled mannitol and cystic fibrosis

p.89-91
Unnecessary bronchial irritation

A double-edged sword?

p.91

Decitabine (New Drug)

p.92-94
Acute myeloid leukaemia: no progress

INN common stem: -afil

p.94

Pertuzumab (New Drug)

p.95
Promising for some women with metastatic breast cancer, but more assessment needed

Tadalafil and benign prostatic hypertrophy (New Indication)

p.96
Too risky

Adverse Effects

Drug-induced corneal damage

p.97-100
Identifying problems in a timely manner is essential

Drug-induced acute pancreatitis

p.101
More and more drugs implicated

Quetiapine: ischaemic colitis

p.101
Like other neuroleptics

Rotavirus vaccines and intussusception

p.102
Studies confirm increased risk

Methylergometrine: adverse effects in breastfed infants

p.102
Do not use this drug

Olmesartan: sprue-like enteropathy

p.102
Losartan or valsartan are the preferred sartans

Reviews

Oncology and haematology in 2013

p.103-105
Some advances, but too many new treatments with an inadequately assessed harm-benefit balance

Drugs to exclude from your list

p.104

New products to avoid

p.105

Treating blood pressure between 140/90 and 160/95 mmHg: no proven benefit

p.106

Outlook

New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps

p.107-110
Marketing authorisations still granted despite inadequate data

Free  Clinical trial rigging: again!

p.110
A systemic problem

Free  Warning: Dangers of insulin at 200 units per ml

p.111
Risk of medication errors

Masthead

Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe